Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

The development of a predictive biomarker for immunotherapy outcome based on flow cytometry test

Descrizione del progetto

Neutrofili: possono prevedere l’esito dell’immunoterapia?

Il sistema immunitario ha molti modi per regolare la forza delle risposte immunitarie, come le proteine dei checkpoint che hanno un ruolo inibitorio sulla funzione delle cellule T. L’inibizione di queste proteine di checkpoint rappresenta una strategia immunoterapica volta a suscitare risposte antitumorali. Questo tipo di immunoterapia presenta tuttavia un successo clinico limitato, senza una chiara evidenza dell’eziologia di fondo. Il progetto BioFlow, finanziato dal CER, si basa sulla scoperta di una sottopopolazione di neutrofili come biomarcatore per la terapia con inibitori del checkpoint immunitario. Dal momento che queste cellule sono presenti nei tumori responsivi, offrono un potente strumento per prevedere la risposta alla terapia e migliorare la progettazione di future strategie di immunoterapia.

Obiettivo

Immunotherapy has revolutionised clinical oncology, with the use of immune checkpoint inhibitors (ICIs). These agents are in clinical use for almost a decade, treating over 20 types of cancers. They have shown a remarkable therapeutic benefit even in patients with advanced disease. Yet, only a small proportion of patients benefit from this therapy, leaving the rest resistant, for reasons that are still not clear. While there are certain clinical biomarkers to predict ICI therapy outcome, their prevalence and prediction power is rather limited. Therefore, there is a clinical unmet need to develop more powerful biomarkers to predict response to immunotherapy. In our ongoing ERC consolidator grant we discovered a unique sub-population of neutrophils, present in peripheral blood, that predicts response to immunotherapy in a very high probability. We designated these cells as immunotherapy-responsiveness cells (IRCs). Using various mouse models, we demonstrate that the levels of circulating IRCs measured at baseline are significantly higher in responding tumours to ICI therapy. These results were confirmed in a limited number of non-small cell lung cancer (NSCLC) and melanoma patients. Hence, our aim is to further test IRC levels in clinical samples, to evaluate their predictive power for ICI therapy, and to develop a clinical liquid biopsy-based predictive biomarker using flow cytometry test. The development of clinical IRC detection based on flow cytometry (BioFlow®) can serve two markets: (1) Clinicians – enabling oncologists to easily predict response to ICI therapy, thus improving personalised immunotherapy treatment; and (2) Pharmaceutical companies - developing immunotherapies - that can use IRC detection in development stages and through clinical studies, enabling tight regulative assessment of R&D success rates. The BioFlow goal is to technically validate and develop a predictive biomarker platform for both markets that will lead to its commercialisation.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Meccanismo di finanziamento

HORIZON-ERC-POC -

Istituzione ospitante

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Contributo netto dell'UE
€ 150 000,00
Costo totale
Nessun dato

Beneficiari (1)